These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34961427)

  • 1. New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and
    Elkady H; Elwan A; El-Mahdy HA; Doghish AS; Ismail A; Taghour MS; Elkaeed EB; Eissa IH; Dahab MA; Mahdy HA; Khalifa MM
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):397-410. PubMed ID: 34961427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
    Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
    Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Thieno[2,3-d]pyrimidines as Anticancer VEGFR-2 Inhibitors with Apoptosis Induction: Design, Synthesis, and Biological and
    Sobh EA; Dahab MA; Elkaeed EB; Alsfouk BA; Ibrahim IM; Metwaly AM; Eissa IH
    Med Chem; 2024; 20(9):876-899. PubMed ID: 38798211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
    Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
    Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies.
    Hassan RM; Ali IH; El Kerdawy AM; Abo-Elfadl MT; Ghannam IAY
    Bioorg Chem; 2024 Nov; 152():107728. PubMed ID: 39178704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
    Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
    El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis,
    Taghour MS; Mahdy HA; Gomaa MH; Aglan A; Eldeib MG; Elwan A; Dahab MA; Elkaeed EB; Alsfouk AA; Khalifa MM; Eissa IH; Elkady H
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2063-2077. PubMed ID: 35875937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and
    Hagras M; Saleh MA; Ezz Eldin RR; Abuelkhir AA; Khidr EG; El-Husseiny AA; El-Mahdy HA; Elkaeed EB; Eissa IH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):380-396. PubMed ID: 34923885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.
    Elkady H; Mahdy HA; Taghour MS; Dahab MA; Elwan A; Hagras M; Hussein MH; Ibrahim IM; Husein DZ; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
    Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130599. PubMed ID: 38521471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors.
    Abdallah AE; Mabrouk RR; Al Ward MMS; Eissa SI; Elkaeed EB; Mehany ABM; Abo-Saif MA; El-Feky OA; Alesawy MS; El-Zahabi MA
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):573-591. PubMed ID: 35012403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Elwan A; Elkady H
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1093-1114. PubMed ID: 34056992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and
    Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers.
    Kassab AE; Gedawy EM; Hamed MIA; Doghish AS; Hassan RA
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):922-939. PubMed ID: 33896327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and cytotoxic evaluation of new thieno[2,3-d]pyrimidine analogues as VEGFR-2/AKT dual inhibitors, apoptosis and autophagy inducers.
    Abd El-Mawgoud HK; AboulMagd AM; Nemr MTM; Hemdan MM; Hassaballah AI; Farag PS
    Bioorg Chem; 2024 Sep; 150():107622. PubMed ID: 38996545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
    El-Metwally SA; Abou-El-Regal MM; Eissa IH; Mehany ABM; Mahdy HA; Elkady H; Elwan A; Elkaeed EB
    Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.